99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

Part of paid clinical trials in Stanford, California.

Sponsor
Andrei Iagaru
Study ID
NCT05891769
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Parathyroid Adenoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • 18Fluorocholine — DRUG
    18F Fluorocholine 5 mCi ± 20% administered intravenously.

Study Details

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT

Key Dates

Start date
Sep 27, 2023
Status verified
Sep 2025
Primary completion
Jul 1, 2026
Completion
Jul 1, 2027

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 18FCH PET/CT
    Participant receive 18F Fluorocholine injection and approximately 45-60 minutes later receive a low dose CT scan from skull base to mid thighs, followed by a static PET emission scan over the same area.

Primary Outcome Measure

Number of lesions detected by PET/CT for detecting parathyroid adenomas. [ Time Frame: up to 1 hour ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Stanford Hospital and ClinicsStanfordCalifornia94305
Meredith Durbahn
[email protected]
Andrei Iagaru, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Stanford, CA

By research site
Stanford Hospital and Clinics· Stanford, CA

Related Studies